文献速递复苏、休克与脓毒症心脑血管急症重症综合管理与镇静镇痛

NULL-PLEASE临床评分在丹麦人群中预测院外心脏骤停结局的外部验证——一项全国性注册研究

External validation of the simple NULL-PLEASE clinical score in predicting outcomes of out-of-hospital cardiac arrest in the Danish population - A nationwide registry-based study.
PubMed 文献 · Resuscitation · 2022-08-22
一句话结论在丹麦全国院外心脏骤停队列中,NULL-PLEASE评分对1天、30天死亡及1年死亡或缺氧性脑损伤的预测AUCROC为0.800–0.828,但高分患者仍有存活者。

该研究基于丹麦2001至2019年全国注册数据,纳入院外心脏骤停后到达医院时恢复自主循环或仍在进行心肺复苏的患者共3881例,外部验证NULL-PLEASE评分(范围0–14)对1天死亡率(主要终点)、30天死亡率及1年死亡或缺氧性脑损伤复合结局的预测能力。NULL-PLEASE评分≥9分(n=244)者1天死亡率为80.7%(95%CI 75.8–85.7%)、30天死亡率为98.0%(95%CI 96.2–99.7%)、复合结局为98.4%(95%CI 96.8–100.0%)。三个结局的AUCROC分别为0.800(95%CI 0.786–0.814)、0.827(95%CI 0.814–0.840)和0.828(95%CI 0.815–0.841)。作者结论认为评分预测能力较高,但即使NULL-PLEASE评分很高,仍有部分患者存活。

要点

  • NULL-PLEASE评分≥9分(n=244)者1天死亡率为80.7%(95%CI 75.8–85.7%),30天死亡率为98.0%(95%CI 96.2–99.7%),复合结局为98.4%(95%CI 96.8–100.0%)。
  • NULL-PLEASE评分预测1天死亡率的AUCROC为0.800(95%CI 0.786–0.814),预测30天死亡率为0.827(95%CI 0.814–0.840),预测复合结局为0.828(95%CI 0.815–0.841)。
  • 全队列1天死亡率为35%,30天死亡率为61%,68%发生1年死亡或缺氧性脑损伤复合结局。
  • 作者结论指出,尽管评分预测能力较高,但即使NULL-PLEASE评分很高,仍有部分患者存活。

适用人群与场景

  • 丹麦2001至2019年全国注册数据中,院外心脏骤停后到达医院时恢复自主循环(ROSC)或仍在进行心肺复苏的患者。

诊断标准与关键阈值

  • NULL-PLEASE评分包含:不可电击心律、无人目击骤停、长时间无血流或低血流期、血pH<7.2、乳酸>7.0 mmol/L、透析终末期肾病、年龄≥85岁、仍在复苏、心外原因;评分范围0–14,以0分为参照。

研究设计与关键结果

  • 研究类型为基于全国注册数据的外部验证研究,纳入3881例院外心脏骤停患者。
  • 主要终点1天死亡率为35%,次要终点30天死亡率为61%,复合结局(1年死亡或缺氧性脑损伤)发生率为68%。
  • NULL-PLEASE评分≥9分(n=244)者1天死亡率为80.7%(95%CI 75.8–85.7%),30天死亡率为98.0%(95%CI 96.2–99.7%),复合结局为98.4%(95%CI 96.8–100.0%)。
  • 预测1天死亡率的AUCROC为0.800(95%CI 0.786–0.814),预测30天死亡率为0.827(95%CI 0.814–0.840),预测复合结局为0.828(95%CI 0.815–0.841)。
  • 作者结论:在院外心脏骤停全国队列中,NULL-PLEASE评分对所有结局的预测AUCROC值均较高,但即使评分很高,仍有部分患者存活。

证据类型、等级与局限

  • 证据类型:基于丹麦全国注册数据的外部验证研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论指出,NULL-PLEASE评分对院外心脏骤停后1天死亡、30天死亡及1年死亡或缺氧性脑损伤的预测AUCROC值均较高,但即使评分很高仍有部分患者存活。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

AIM: The NULL-PLEASE score (Nonshockable rhythm, Unwitnessed arrest, Long no-flow or Long low-flow period, blood pH < 7.2, Lactate > 7.0 mmol/L, End-stage renal disease on dialysis, Age ≥85 years, Still resuscitation, and Extracardiac cause) may identify patients with out-of-hospital cardiac arrest (OHCA) unlikely to survive. We aimed to validate the NULL-PLEASE score in a nationwide setting.

METHODS: We used Danish nationwide registry data from 2001 to 2019 and identified OHCA survivors with return of spontaneous circulation (ROSC) or ongoing cardiopulmonary resuscitation at hospital arrival. The primary outcome was 1-day mortality. Secondary outcomes were 30-day mortality and the combined outcome of 1-year mortality or anoxic brain damage. The risks of outcomes were estimated using logistic regression with a NULL-PLEASE score of 0 as reference (range 0-14). The predictive ability of the score was examined using the area under the receiver operating characteristics (AUCROC) curve.

RESULTS: A total of 3,881 patients were included in the analyses. One-day mortality was 35%, 30-day mortality was 61%, and 68% experienced the combined outcome. For a NULL-PLEASE score ≥9 (n = 244) the absolute risks were: 1-day mortality: 80.7% (95% confidence interval [CI]: 75.8-85.7%); 30-day mortality: 98.0% (95% CI: 96.2-99.7%); and the combined outcome: 98.4% (95% CI: 96.8-100.0%). Corresponding AUCROC values were 0.800 (95% CI: 0.786-0.814) for 1-day mortality, 0.827 (95% CI: 0.814-0.840) for 30-day mortality, and 0.828 (95% CI: 0.815-0.841) for the combined outcome.

CONCLUSIONS: In a nationwide OHCA-cohort, AUCROC values for the predictive ability of NULL-PLEASE were high for all outcomes. However, some survived even with high NULL-PLEASE scores.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Byrne C, Barcella CA, Krogager ML, et al. External validation of the simple NULL-PLEASE clinical score in predicting outcomes of out-of-hospital cardiac arrest in the Danish population - A nationwide registry-based study. Resuscitation. 2022. PMID: 36007857. doi:10.1016/j.resuscitation.2022.08.009

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。